807 related articles for article (PubMed ID: 30476584)
1. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
3. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ; D'Haens GR; Sands BE; Panaccione R; Ng SC; Lawendy N; Kulisek N; Modesto I; Guo X; Mundayat R; Su C; Vranic I; Panés J
J Crohns Colitis; 2023 Apr; 17(3):338-351. PubMed ID: 36124702
[TBL] [Abstract][Full Text] [Related]
6. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Curtis JR; Regueiro M; Yun H; Su C; DiBonaventura M; Lawendy N; Nduaka CI; Koram N; Cappelleri JC; Chan G; Modesto I; Lichtenstein GR
Inflamm Bowel Dis; 2021 Aug; 27(9):1394-1408. PubMed ID: 33324993
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
Panés J; D'Haens GR; Sands BE; Ng SC; Lawendy N; Kulisek N; Guo X; Wu J; Vranic I; Panaccione R; Vermeire S
United European Gastroenterol J; 2024 May; ():. PubMed ID: 38778549
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
Loftus EV; Baumgart DC; Gecse K; Kinnucan JA; Connelly SB; Salese L; Su C; Kwok KK; Woolcott JC; Armuzzi A
Inflamm Bowel Dis; 2023 May; 29(5):744-751. PubMed ID: 35792493
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
Sands BE; Long MD; Reinisch W; Panés J; Loftus EV; Nduaka CI; Soonasra A; Mundayat R; Lawendy N; Chan G; Friedman GS; Su C
Inflamm Bowel Dis; 2022 Feb; 28(2):234-245. PubMed ID: 33742652
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Matsuoka K; Hisamatsu T; Kim HJ; Ye BD; Arai S; Hoshi M; Yuasa H; Tabira J; Toyoizumi S; Shi N; Woo JS; Hibi T
J Gastroenterol Hepatol; 2022 Oct; 37(10):1884-1892. PubMed ID: 35734858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
